MedinCell S.A. (MEB.F)

14,82 0,00 (0,00%) Ab 03:29PM CEST. Markt geöffnet.

MedinCell S.A.

3 rue des FrEres LumiEre
Jacou 34830
France
33 4 67 02 13 67
https://www.medincell.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 138

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Christophe Douat	CEO & Chairman of Executive Board	392,77k	N/A	1966
Mr. Franck Pouzache	Chief People Officer & Member of the Management Board	198,89k	N/A	N/A
Stephane Postic	Chief Financial Officer	N/A	N/A	N/A
Julie Alimi	Head of Legal	N/A	N/A	N/A
Mr. David Heuze	Head of Communications	N/A	N/A	N/A
Mr. Adolfo Lopez-Noriega	Head of Research & Development	N/A	N/A	N/A
Mr. Sebastien Enault	Chief Business Officer	N/A	N/A	N/A
Ms. Helen Martin	Head of Alliance & Project Management	N/A	N/A	N/A
Ms. Quiterie De Beauregard	Head of Global Health Development	N/A	N/A	N/A
Dr. Richard Malamut M.D.	Chief Medical Officer	N/A	N/A	1960

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

Corporate Governance

MedinCell S.A.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 9, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.